BridgeBio Oncology Therapeutics
Market cap $156M 80.3M shares (10-Q, Nov 5, 2026) × $1.94 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- BBOT pipeline BBO-11818 Ph1 readout2H 2026BBOT pipeline BBO-11818 Ph1 readout, 2H 2026, major
- BBO-11818 Ph1 interim4Q 2026BBO-11818 Ph1 interim, 4Q 2026, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
BBO-10203
Discontinued (2)
- BBO-8520 — Non-Small Cell Lung Cancer · strategic deprioritization due to evolving treatment landscape, competitive crowding, and portfolio dynamics
- BBO-10203 — Breast Cancer · strategic deprioritization due to evolving treatment landscape, competitive crowding, and portfolio dynamics
Capital (as filed)
- Cash
- $76.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $117M Sep 30, 2026
- Long-term investments
- $121M Sep 30, 2026
- Operating cash flow
- −$28.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $315M cash, runway 2029 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Offering documents (4)
- 2026-09-01 S-3 · Shelf registration
- 2026-08-12 424B3 · Resale (selling stockholders)
- 2026-06-22 424B3 · Resale (selling stockholders)
- 2026-05-13 424B3 · Resale (selling stockholders)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (6)
- 2026-11-11 UPDATE: BridgeBio Oncology (BBOT) - Trading Below Cash
- 2026-09-08 UPDATE: BridgeBio Oncology (BBOT) - The n Finally Moved 🔒 Paid
- 2026-09-02 UPDATE: BridgeBio Oncology (BBOT) - The ATM Arrives Ninety Days Early 🔒 Paid
- 2026-08-12 UPDATE: BridgeBio Oncology (BBOT) - The Internal Combo Leaves the Lab 🔒 Paid
- 2026-04-27 UPDATE: BridgeBio Oncology (BBOT) - The CSO Takes the Wheel, the FDA Hands Out a Hall Pass 🔒 Paid
- 2026-04-20 BridgeBio Oncology (BBOT) - Scientific Deep Dive for BBO-8520, BBO-11818, and BBO-10203 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (6 calls)
Every verdict Biotech Distilled has published on BridgeBio Oncology Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-20 Watch BridgeBio Oncology (BBOT) - Scientific Deep Dive for BBO-8520, BBO-11818, and BBO-10203 Elegant science and pristine balance sheet, but micro-cohort data and high clinical risk warrant staying on the sidelines until Phase 1b/2 expansion data matures in late 2026.
- 2026-04-27 Watch UPDATE: BridgeBio Oncology (BBOT) - The CSO Takes the Wheel, the FDA Hands Out a Hall Pass Fast Track designation, C-suite reshuffle signaling M&A/pivotal-trial ambitions, and supportive AACR preclinical data modestly strengthen the thesis, but the n remains too small to act.
- 2026-08-12 Watch UPDATE: BridgeBio Oncology (BBOT) - The Internal Combo Leaves the Lab Internal KRAS+PI3Kα combinations are now dosing in patients and execution is on track, but the efficacy dataset is unchanged and the clock is short enough that entry now means buying into a binary.
- 2026-09-02 Watch UPDATE: BridgeBio Oncology (BBOT) - The ATM Arrives Ninety Days Early A $200M ATM filed 90 days before binary readouts makes the downside shape worse without changing the science, keeping the stance on Watch while flagging dilution risk.
- 2026-09-08 Speculative buy speculative UPDATE: BridgeBio Oncology (BBOT) - The n Finally Moved BBO-8520 monotherapy ORR held at 63% as the cohort tripled to 41 patients with no grade 3 liver elevations, materially de-risking the efficacy-erosion failure mode, though the commercial ceiling narrowed to a 2L+ salvage niche and confirmatory data slipped to mid-2027.
- 2026-11-11 Hold UPDATE: BridgeBio Oncology (BBOT) - Trading Below Cash Stock collapsed 75% to trade below cash ($3.93/share net cash vs $2.20 price), but CMO departure ahead of Q4 readouts and lead indication's dependency on third-party Phase 3 wins argue against adding; existing holders should hold through Q4 monotherapy update.
- Long call · opened Sep 9, 2026 at $6.75 · -71.3% vs XBI -8.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (6 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Updated clinical data are expected in the second half of 2026.”
matched to BBO-10203 · readout other -
“Updated Phase 1 clinical data are expected in the second half of 2026.”
matched to BBO-11818 · interim data -
“Updated clinical data are expected in the second half of 2026 and an internal combination study with BBO-10203 opened in April 2026.”
matched to BBO-8520 · readout other · since happened Sep 8, 2026
-
-
-
“Updated clinical data are expected in the second half of 2026.”
matched to BBO-10203 · readout other -
“Updated Phase 1 clinical data are expected in the second half of 2026.”
matched to BBO-11818 · interim data -
“Updated clinical data are expected in the second half of 2026 and an internal combination study with BBO-10203 opened in April 2026.”
matched to BBO-8520 · readout other · since happened Sep 8, 2026
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (31)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseBBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress→ BD update
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD update
- Nov 10, 202610-QQuarterly report→ BD update
- Nov 5, 20268-KCurrent report: officer / director change
- Sep 8, 2026ReleaseBBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers→ BD updateSummary on the 8-KBD extracted 2 program updates from this document → BBOT pipeline
- Sep 8, 20268-KCurrent report: other events · EX-99.1→ BD updateThe 2H 2026 data has arrived: BBO-8520 monotherapy holds its ORR at scale (63%, n=41) with a 100% disease control rate and zero Grade 3 liver events, while the pembrolizumab combo in inhibitor-experienced NSCLC hits 75% ORR at the lead dose — and BBOT just declared its strategic endgame.BD extracted 5 program updates from this document → BBOT pipeline
- Sep 1, 2026S-3Shelf registration→ BD updateBBOT quietly filed a $500M shelf and activated a $200M ATM facility on the same day it registered 63M legacy shares for resale — materially changing the dilution picture heading into the 2H 2026 data catalysts.
- Sep 1, 2026ReleaseBBOT to Participate in Upcoming Investor Healthcare Conferences→ BD updateSummary on the S-3
- Aug 12, 2026424B3Prospectus (resale / update)
- Aug 11, 2026ReleaseBBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jul 6, 2026SCHEDULE 13D/A13D amendment
- Jun 22, 20268-KCurrent report: officer / director change, shareholder vote
- Jun 22, 2026424B3Prospectus (resale / update)
- May 13, 2026424B3Prospectus (resale / update)
- May 12, 2026ReleaseBBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- May 6, 2026424B3Prospectus (resale / update)
- Apr 29, 20268-KCurrent report: officer / director change
- Apr 29, 2026424B3Prospectus (resale / update)
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Apr 23, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Apr 23, 2026424B3Prospectus (resale / update)
- Mar 26, 20268-KCurrent report: officer / director change
- Mar 26, 2026424B3Prospectus (resale / update)
- Mar 6, 2026424B3Prospectus (resale / update)
- Mar 5, 20268-KCurrent report: results of operations · EX-99.1
- Mar 5, 202610-KAnnual report
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Sep 10, 2026EFFECTRegistration effective
- Sep 8, 2026EFFECTRegistration effective→ BD updateSummary on the 8-K
- Sep 1, 2026POS AMPost-effective amendment→ BD updateSummary on the S-3
- May 4, 2026EFFECTRegistration effective
- Apr 30, 2026POS AMPost-effective amendment
- Apr 28, 2026ARSAnnual report to shareholders